espoan 40mg

Espoan is a medicine used đồ sộ treat ulcers of the stomach, duodenum, esophagitis as well as other symptoms of the gastrointestinal tract. On the market today, there is a lot of information about Espoan products, but it is still incomplete. To better understand what Espoan is, and what are the uses of analgin, let's read more of the article below.

Bạn đang xem: espoan 40mg

Espoan 40mg and 20mg Espoan of Sterling Healthcare (India) pharmaceutical company, the main ingredient is esomeprazole, belonging đồ sộ the class of proton pump inhibitors (PPIs). The main ingredient of Espoan is esomeprazole, which belongs đồ sộ the group of antacids, anti-reflux and anti-ulcer drugs. The drug is prepared in the size of 20mg and 40mg tablets, by Sterling Healthcare Pvt. Ltd. - Indian manufacture.
Main ingredients in each Espoan tablet include:
Espoan 20mg tablet : 20mg tablet contains trăng tròn mg of esomeprazole (as magnesium dihydrate), sucrose 43.7 mg and lactose (as lactose monohydrate 67.5 mg), 0.03 mg of sodium.
Espoan 40mg : 40mg tablets contain 40 mg of esomeprazole (as magnesium dihydrate), sucrose 87.4 mg and lactose (as lactose monohydrate 100.125 mg), 0.06 mg sodium.
Espoan is prescribed by a doctor for use in the following cases:

Xem thêm: Uống hạt muồng nhiều có tốt không?

Xem thêm: agitritine 200

2.1 Pharmacodynamic effects Omeprazole has two isoforms, R and S, and Esomeprazole is the S isomer that reduces gastric acid secretion through a more specific, targeted mechanism of action. Esomeprazole is a specific inhibitor of the acid pump in parietal cells. The essence of Esomeprazole is a weak base and is concentrated, when in the highly acidic environment of the secretory tubules of parietal cells, it will convert đồ sộ the active size, which is also where it inhibits the enzyme H + K + -ATPase - pumps acid and inhibits both basal acid secretion and stimulates secretion.
2.2 Pharmacokinetic properties * Absorption
Esomeprazole is acid labile and is administered orally as gastric resistant granules. In vivo conversion đồ sộ the R-isomer of omeprazole is negligible. Absorption of esomeprazole is rapid, with peak plasma concentrations occurring approximately 1 đồ sộ 2 hours after the recommended dose. Absolute bioavailability is 64% after a single 40 mg dose and increases đồ sộ 89% after repeated once-daily dosing. For the trăng tròn mg dose of esomeprazole, the figures for the above values ​​are 50% and 68%, respectively.
Co-administration with food slows and decreases the absorption of esomeprazole, but this does not significantly affect the effect of esomeprazole on gastric acidity.
* Distribution
In healthy subjects, the steady-state volume of distribution is approximately 0.22 l/kg body toàn thân weight. Esomeprazole is up đồ sộ 97% bound đồ sộ plasma proteins.
* Bioconversion
The cytochrome P450 (CYP) system acts đồ sộ cause Esomeprazole đồ sộ be completely metabolized. The polymorphic CYP2C19 is a major part of esomeprazole metabolism, responsible for the formation of the desmethyl and hydroxy metabolites of esomeprazole. The remainder depends on CYP3A4, responsible for the formation of esomeprazole sulphone, which serves as the major plasma metabolite.
* Elimination
For people with a functional CYP2C19 enzyme or in other words, those who are heavy metabolizers.
Total plasma clearance after single dosing is about 17 l/h and after repeated administration is about 9 l/h. The plasma half-life after repeated once-daily administration is approximately 1.3 hours. When administered once daily, Esomeprazole is completely eliminated from plasma with no tendency đồ sộ accumulate.
The major metabolites of esomeprazole have no effect on gastric acid secretion. Approximately 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remaining 20% ​​in the feces. Less than thở 1% of the generic drug was recovered in the urine.
2.3 Contraindications of Espoan Patients who are allergic đồ sộ any of the ingredients or excipients of Espoan should not be used concurrently with nelfinavir 2.4. Side effects of Espoan * Common
Headache, nausea, vomiting, abdominal pain, flatulence, diarrhea, constipation.
* Uncommon
Itching, dermatitis, urticaria Dizziness, blurred vision. Dry mouth. * Rarely
Anaphylactic reactions, hypersensitivity reactions such as angioedema Increased liver enzymes. Stevens Johnson syndrome, erythema multiforme Myalgia. 2.5. Drug interactions * Drug products with pH dependent absorption
Suppressing gastric acid during treatment with esomeprazole and other PPIs may decrease or increase the absorption of medicinal products with absorption The absorption depends on the pH in the stomach. As with other medicinal products that reduce stomach acid, the absorption of medicinal products such as ketoconazole, itraconazole and erlotinib may be decreased and the absorption of digoxin may be increased during treatment with esomeprazole.
* Protease Inhibitors
Omeprazole interacts with some protease inhibitors. Increased gastric pH during treatment with omeprazole may alter the absorption of protease inhibitors. Other possible mechanisms of interaction are through inhibition of CYP 2C19. Because of the similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and the S-esomeprazole isomer, co-administration of esomeprazole with atazanavir is not recommended and concomitant use of esomeprazole and nelfinavir is contraindicated.
2.6. Precautions for long-term use of Espoan:
Patients on long-term therapy (especially those treated for more than thở one year) should be monitored regularly.
Absorption of Vi-Ta-Min B12 :
Esomeprazole, lượt thích all acid-blocking medicines, may decrease absorption of Vi-Ta-Min B12 (cyanocobalamin) due đồ sộ decreased or achlorhydria. This should be considered in patients with reduced body toàn thân stores or risk factors for reduced Vi-Ta-Min B12 absorption during long-term therapy.
Hypokalemia:
Severe hypokalemia has been reported in patients treated with proton pump inhibitors (PPIs) such as esomeprazole for at least three months and in most cases one year. Severe manifestations of hypocalcaemia such as fatigue, malaise, delirium, convulsions, dizziness, and ventricular arrhythmias may occur, but they may begin insidiously and go unnoticed. In most affected patients, hypokalemia improved after magnesium replacement and PPI discontinuation.
For patients expected đồ sộ be on prolonged therapy or who take PPIs together with digoxin or medicinal products that can cause hypokalemia (e.g. diuretics), healthcare professionals Consider measuring magnesium levels before initiating PPI therapy and periodically during treatment.
Risk of fracture:
Proton pump inhibitors, especially if used in high doses and for long periods of time (> 1 year), may slightly increase the risk of hip, wrist and spine fractures, predominantly in the elderly or with other recognized risk factors. Observational studies suggest that proton pump inhibitors can increase the overall risk of fracture by 10–40%. Some of this increase may be due đồ sộ other risk factors. Patients at risk for osteoporosis should be cared for according đồ sộ current clinical guidelines and they should be adequately supplemented with Vi-Ta-Min D and calcium.
Subacute cutaneous lupus erythematosus (SCLE):
Proton pump inhibitors have been associated with very rare cases of SCLE. If lesions occur, especially in areas of skin exposed đồ sộ the sun, and if accompanied by joint pain, the patient should seek prompt medical help and a healthcare professional should consider stop esomeprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.

3.1 Espoan trăng tròn mg * Adults
Gastroesophageal reflux disease (GERD):
+ Treatment of erosive reflux esophagitis: 40mg esomeprazole once daily for 4 weeks. An additional 4 weeks of treatment is recommended for patients with esophagitis that has not healed or has persistent symptoms.
+ Long-term use for patients with healed esophagitis đồ sộ prevent recurrence: trăng tròn mg x 1 time / day.
+ Symptomatic treatment of gastroesophageal reflux disease (GERD): trăng tròn mg once daily in patients without esophagitis. If symptom control is not achieved after 4 weeks of treatment, the patient should receive further treatment.
When symptoms have resolved, control symptoms with a dose of 20mg x 1 time / day.
In combination with appropriate antibacterial treatment regimens for eradication of Helicobacter pylori
+ Healing of duodenal ulcers associated with Helicobacter pylori and prevention of recurrence of peptic ulcers in patients with Helicobacter ulcers pylori: 20mg esomeprazole + 1g amoxicillin + 500mg clarithromycin, taken twice daily for 7 days.
Patients requiring continued NSAID therapy
+ Healing of gastric ulcers associated with NSAID therapy: The recommended dose is trăng tròn mg once daily. Duration of treatment is 4 đồ sộ 8 weeks.
+ Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients with risk factors: trăng tròn mg once daily.
Treatment of Zollinger Ellison syndrome
The starting dose is esomeprazole 40 mg twice daily. The dosage should then be adjusted individually according đồ sộ the doctor's orders. Most patients can be controlled with daily doses of esomeprazole between 80 and 160 mg. With doses of esomeprazole above 80 mg per day, the dose should be divided and administered twice daily.
* Adolescents from 12 years old
Gastroesophageal reflux disease (GERD):
Dosage is the same as adults
Treatment of duodenal ulcers caused by Helicobacter pylori
Treatment should be under the supervision of a specialist. .
* Children under 12 years old
Esomeprazole 20mg gastro-resistant tablets should not be given đồ sộ children under 12 years of age.
* Renal impairment
No dose adjustment is required in patients with impaired renal function. Due đồ sộ limited experience in patients with severe renal impairment, these patients should be treated with caution.
* Hepatic impairment
No dose adjustment is required in patients with mild đồ sộ moderate hepatic impairment. For patients with severe hepatic impairment, the maximum dose of trăng tròn mg esomeprazole should not be exceeded.
3.2 Esomeprazole 40 mg * Adults
Gastroesophageal reflux disease (GERD)
+ Treatment of erosive reflux esophagitis: 40mg once daily for 4 weeks. An additional 4 weeks of treatment is recommended for patients with esophagitis that has not completely healed or has persistent symptoms.
+ Prolonged treatment after intravenous administration đồ sộ prevent peptic ulcer re-bleeding: 40 mg once daily for 4 weeks
Treatment of Zollinger Ellison syndrome
The recommended starting dose is esomeprazole 40 mg x 2 times / day. The dosage should then be adjusted individually according đồ sộ the doctor's orders. The majority of patients can be controlled with daily doses of esomeprazole between 80 and 160 mg. With doses of esomeprazole above 80 mg per day, the dose should be divided and administered twice daily.
* Children under 12 years of age
Esomeprazole should not be given đồ sộ children as no data are available.
* Renal impairment
No dose adjustment is required in patients with impaired renal function. Because experience in the treatment of patients with severe renal impairment is limited, caution should be exercised in these patients.
* Hepatic impairment
No dose adjustment is required in patients with mild đồ sộ moderate hepatic impairment. For patients with severe hepatic impairment, a maximum dose of trăng tròn mg of esomeprazole per day should not be exceeded.